NCT04369534View on ClinicalTrials.gov

Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction

PHASE4CompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

December 1, 2015

Primary Completion Date

November 30, 2019

Study Completion Date

December 1, 2019

Conditions
Acute Coronary SyndromeSTEMINSTEMI - Non-ST Segment Elevation MIPLATELET AGGREGATIONINDIVIDUALIZED THERAPY
Interventions
DRUG

Clopidogrel

Adjusting clopidogrel dosage according to platelet reactivity results during 12 months after PCI

DRUG

Ticagrelor

Administration of standard dose of ticagrelor during 12 months after PCI

Trial Locations (1)

10000

Uhiversity hospital Center Zagreb, Zagreb

All Listed Sponsors
collaborator

Croatian Science Foundation

OTHER_GOV

collaborator

Clinical Hospital Centre Zagreb

OTHER

lead

University of Zagreb

OTHER

NCT04369534 - Efficacy and Safety of Individualized P2Y12 Receptor Antagonists Treatment Based on Agregometry Versus Fixed Dose Regimen in Patients After Acute Myocardial Infarction | Biotech Hunter | Biotech Hunter